Financial Performance - The company's revenue for Q3 2023 was ¥58,524,256.85, a decrease of 25.19% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥5,542,080.66, representing a decline of 128.22% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥5,553,105.45, down 121.53% from the previous year[5]. - Total operating revenue for Q3 2023 was CNY 179,935,611.58, a decrease of 8.4% compared to CNY 196,626,339.15 in the same period last year[17]. - Net loss for Q3 2023 was CNY 46,056,930.81, compared to a net loss of CNY 38,626,058.29 in Q3 2022, representing an increase in loss of 19.0%[18]. - Basic and diluted earnings per share were both CNY -0.0421, compared to CNY -0.0343 in the same quarter last year[18]. Cash Flow - The operating cash flow net amount for the year-to-date was ¥538,414.39, a significant decrease of 95.09% compared to the same period last year[5]. - The cash inflow from operating activities for the current period was ¥203,759,956.42, a decrease of 6.0% compared to ¥216,954,395.65 in the previous period[19]. - The net cash flow from operating activities was ¥538,414.39, significantly lower than ¥10,971,676.12 in the previous period, indicating a decline in operational efficiency[19]. - Cash outflow for purchasing goods and services increased to ¥34,645,255.46 from ¥24,617,513.56, representing a rise of 40.7%[19]. - The total cash outflow from financing activities was ¥22,277,458.00, up from ¥17,628,250.30, marking an increase of 26.8%[20]. - The net cash flow from financing activities was -¥6,277,458.00, compared to -¥1,628,250.30 in the previous period, indicating increased financial strain[20]. - The cash and cash equivalents at the end of the period decreased to ¥20,210,996.60 from ¥31,101,762.07, a decline of 35.2%[20]. - The cash received from tax refunds increased to ¥455,208.80 from ¥16,549.61, showing a significant improvement in cash flow from tax-related activities[19]. - The company did not report any cash inflow from investment activities, maintaining a consistent lack of investment returns[19]. Assets and Liabilities - The total assets at the end of the reporting period were ¥698,674,418.40, down 5.34% from the end of the previous year[5]. - Current assets totaled CNY 544,708,119.50, down from CNY 564,819,858.63, indicating a decrease of about 3.9%[14]. - Cash and cash equivalents decreased to CNY 20,710,678.29 from CNY 28,180,123.46, representing a decline of approximately 26.5%[14]. - Accounts receivable decreased to CNY 78,387,326.41 from CNY 100,116,017.59, a reduction of about 21.7%[14]. - Inventory increased to CNY 416,023,046.03 from CNY 408,764,642.59, showing a slight increase of approximately 1.5%[14]. - Non-current assets totaled CNY 153,966,298.90, down from CNY 173,258,603.92, reflecting a decrease of about 11.1%[14]. - The total liabilities increased to CNY 151,235,995.48, up from CNY 144,583,108.82, reflecting a growth of 4.5%[17]. - The total equity attributable to shareholders decreased to CNY 513,923,372.90 from CNY 557,240,851.04, a decline of 7.7%[17]. Research and Development - Research and development expenses for the reporting period were ¥21,816,849.53, a decrease of 52.67% year-on-year due to a reduction in R&D projects[10]. - The company's R&D expenses were CNY 21,816,849.53, significantly reduced by 52.7% from CNY 46,092,889.94 in the previous year[17]. - The company reported a significant reduction in development expenditures from CNY 15,580,000.00 to CNY 10,980,000.00, a decrease of approximately 29.8%[14]. Shareholder Information - The company reported a total of 100,517 ordinary shareholders at the end of the reporting period[10]. - The company has a total of 147,381,643 shares held by major shareholders, with the largest shareholder, Yu Qinfeng, holding 14.32%[11]. - The company has no outstanding preferred shareholders as per the report[12]. - The company is actively managing its shareholder structure, with significant pledges and freezes on shares held by major shareholders[11]. Future Outlook - Future outlook includes a commitment to enhance product development and market expansion strategies, although specific numerical targets were not provided[16]. - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[21].
四环生物(000518) - 2023 Q3 - 季度财报